AnGes ^None

AnGes MG, Inc. is a biopharmaceutical company that focuses on developing gene medicine for patients suffering from diseases for which there is no effective therapy. They have already marketed Naglazyme, a drug for mucopolysaccharidosis VI, and are in the last stage of clinical development for HGF Plasmid, a gene therapy for critical limb ischemia. They are also developing NF-B decoy oligonucleotide, a nucleic acid medicine that suppresses various types of inflammation. AnGes was founded in 1999 and aims to become a global leader in the field of gene medicine.